Vir Biotechnology announces a proposed public offering
FROM THE WIRE · BUSINESSWIRE.COM
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA new share offering can weigh on the stock through dilution.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Vir Biotechnology intends to offer common stock in an underwritten public offering.
- 02The underwriters receive a 30-day option to buy up to an additional 15% of shares.
- 03The company is a clinical-stage biopharma focused on infectious diseases and cancer.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets